Caffeic acid phenethyl ester (CAPE) exhibits significant potential as an antidiabetic and liver-protective agent in streptozotocin-induced diabetic rats

Basit Öğe Kaydı
dc.authoridTuzcu, Mehmet/0000-0003-3118-1054
dc.contributor.authorCelik, Sefa
dc.contributor.authorErdogan, Suat
dc.contributor.authorTuzcu, Mehmet
dc.date.accessioned2024-09-18T20:15:09Z
dc.date.available2024-09-18T20:15:09Z
dc.date.issued2009
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractCaffeic acid phenethyl ester (CAPE) was screened for hypoglycemic and liver-protective activity in streptozotocin (STZ)-induced diabetic rats. Diabetes was established by single dose STZ injection (45 mg kg(-1) bw, i.p.) for 48h.CAPE wasinjected atdoses of 10, 20 and 30 mu Mkg(-1) bw day(-1) (i.p.) to the rats in CAPEI, CAPEII and CAPEIII groups 2 days after induction of diabetes and continued for 60 days, thereafter. It was found that diabetes down-regulated the expressions of glucokinase (7.8-fold) and pyruvate kinase (6.4-fold) in comparison to control, however, phoshoenolpyruvate carboxykinase mRNA levels were up-regulated by 2.2-fold. CAPE treatments enhanced the expressions of glucokinase (3.4-14.9-folds), and pyruvate kinase (3.2-12.8-folds) mRNAs in diabetic rats. However, phoshoenolpyruvate carboxykinase mRNA expression was decreased by CAPE to varying degrees (1.2-5.5-fold). CAPE increased (similar to 2-fold) the level of plasma insulin previously decreased by STZ treatment. Here we demonstrate that CAPE significantly decreased the fasting blood levels of glucose, alanine aminotransferase, cholesterol, and triglyceride induced by diabetes. CAPE increased the liver glycogen level lowered by diabetes. In histopathological evaluation of the liver, CAPE treatments were seen to reduce necrosis and anisonucleosis in hepatocytes, and connective tissue elevated in the portal region by diabetes. CAPE exhibits a significant potential as an antidiabetic agent by suppressing hepatic glucose output via inducing mRNA expression of glucokinase and pyruvate kinase, whilst inhibiting phoshoenolpyruvate carboxykinase in diabetes. CAPE also has the ability to decrease the harmful effects of diabetes on the liver of rats. (C) 2009 Elsevier Ltd. All rights reserved.en_US
dc.description.sponsorshipScientific and Technological Research Council of Turkey, TUBITAK [1050647]en_US
dc.description.sponsorshipThis study was supported by a grant from the Scientific and Technological Research Council of Turkey, TUBITAK (project no. 1050647). We thank Dr. Sandra Spence (Scotland/UK) for the English revision.en_US
dc.identifier.doi10.1016/j.phrs.2009.03.017
dc.identifier.endpage276en_US
dc.identifier.issn1043-6618
dc.identifier.issue4en_US
dc.identifier.pmid19717012en_US
dc.identifier.scopus2-s2.0-69249203820en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage270en_US
dc.identifier.urihttps://doi.org/10.1016/j.phrs.2009.03.017
dc.identifier.urihttps://hdl.handle.net/20.500.12483/9480
dc.identifier.volume60en_US
dc.identifier.wosWOS:000270056500009en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAcademic Press Ltd- Elsevier Science Ltden_US
dc.relation.ispartofPharmacological Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectDiabetesen_US
dc.subjectCaffeic acid phenethyl esteren_US
dc.subjectGlucose metabolismen_US
dc.subjectLiveren_US
dc.titleCaffeic acid phenethyl ester (CAPE) exhibits significant potential as an antidiabetic and liver-protective agent in streptozotocin-induced diabetic ratsen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ N/A ]
İsim:
Tam Metin / Full Text
Boyut:
1.24 MB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu